MedTrace Logo

Levetiracetam for Painful Polyneuropathy

NCT00286260 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-12-18

No results posted yet for this study

Summary

Polyneuropathy of different etiologies is often associated with pain. The standard treatment of this pain is anticonvulsants or antidepressants, but none of these treatment are effective or tolerable for all patients. Levetiracetam is a newer anticonvulsant and it is the hypothesis is that it could relieve neuropathic pain in polyneuropathy. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3.000 mg/day on pain in polyneuropathy

Conditions

  • Painful Polyneuropathy

Interventions

DRUG

levetiracetam

Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Søren H Sindrup, Professor · Department of Neurology, Odense Unviersity Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-08-31
Completion
2008-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00286260 on ClinicalTrials.gov